The role of the NFκB signalling pathway in cancer

Clinical and Translational Oncology

Volumn 10, Issue 3, 2008, Pages 143-147

  Sempere, María Cortés ^a   Fanjul, Vanesa Rodríguez ^a   Pérez, Isabel Sánchez ^a   Perona, Rosario ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Bortezomib; I B; IKK; NF B; Rel

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; 6 CHLORO 7 METHOXY 8 (2 METHYLNICOTINAMIDO) BETA CARBOLINE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; BORTEZOMIB; CARBOPLATIN; CD40 ANTIGEN; DNA 26S; GEMCITABINE; I KAPPA B; I KAPPA B KINASE GAMMA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; NF KAPPA B2; PEMETREXED; PLATINUM COMPLEX; PROTEASOME INHIBITOR; PROTEIN BCL 3; PROTEIN BCL XL; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GROWTH; CARCINOGENESIS; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; ENZYME DEGRADATION; ENZYME INHIBITION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; NEOPLASM; NONHUMAN; OVARY CANCER; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

HUMANS; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 45549093584     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-008-0171-3     Document Type: Article

References (28)

1. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8:49-62
2. Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288
3. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195-2224
4. Perkins ND (2003) Oncogenes, tumor suppressors and p52 NF-kappaB. Oncogene 22:7553-7556
5. Kalaitzidis D, Ok J, Sulak L 2nd et al (2004) Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene 23:7580-7587
6. Fukuhara N, Tagawa H, Kameoka Y et al (2006) Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma. Cancer Sci 97:499-504
7. Barth TF, Bentz M, Leithäuser F et al (2001) Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes Cancer 31:316-325
8. Neri A, Fracchiolla NS, Migliazza A et al (1996) The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Leuk Lymphoma 23:43-48
9. Hinz M, Löser P, Mathas S et al (2001) Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 97:2798-2807
10. Bours V, Franzoso G, Azarenko V et al (1993). The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72: 729-739
11. Van Waes C (2007). Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13:1076-1082
12. Wang CY, Mayo MW, Korneluk RG et al (1998). NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680-1683
13. Guttridge DC, Albanese C, Reuther JY et al (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785-5799
14. Chen C, Edelstein LC, Gélinas C (2000) The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20:2687-2695
15. Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33-47
16. Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121
17. Davis NB, Taber DA, Ansari RH et al (2004). Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol 22:115-119
18. Kondagunta GV, Drucker B, Schwartz L et al (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22:3720-3725
19. Markovic SN, Geyer SM, Dawkins F et al (2005) A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103:2584-2589
20. Mackay H, Hedley D, Major P et al (2005) A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11:5526-5533
21. Yang CH, Gonzalez-Angulo AM, Reuben JM et al (2006) Bortezomib (VELCADE) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17:813-817
22. Ramirez PT, Landen CN Jr, Coleman RL et al (2008). Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum-and taxane-resistant ovarian cancer. Gynecol Oncol 108:68-71
23. Davies AM, Ho C, Metzger AS et al (2007) Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol 2:1112-1116
24. Davies AM, Ruel C, Lara PN et al (2008) The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: A California Cancer Consortium Phase I study. J Thorac Oncol 3:68-74
25. Yang J, Amiri KI, Burke JR et al (2006) BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: Involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 12:950-960
26. Lam LT, Davis RE, Pierce J et al (2005) Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11:28-40
27. Cilloni D, Messa F, Arruga F et al (2006) The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 20:61-67
28. Yemelyanov A, Gasparian A, Lindholm P et al (2006) Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 25:387-389